- Oxford BioDynamics said it had been granted a key patent in the US for its EpiSwitch biomarker technology.

The patent, issued by the US Patent and Trademark Office, covers proprietary EpiSwitch designs for high resolution discovery and monitoring of regulatory conditional chromosome conformation signatures.

Counterparts to the patent have already been granted in Europe, China, Japan, Australia, Hong Kong, New Zealand, Singapore and South Africa.

At 8:06am: [LON:OBD] Oxford Biodynamics Plc share price was +4.63p at 198p

Story provided by